A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss
NCT04450589 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46
Last updated 2020-06-30
Summary
To demonstrate that the ALRV5XR multi-molecular targeting treatment regimen of a daily shampoo, conditioner, topical serum and oral supplement is superior to placebo in promoting hair growth as assessed by change in hair density and percentage of terminal hair regrowth after ALRV5XR therapy.
This will be a single-centre, double-blind, randomized, placebo-controlled study in male subjects randomized to a 1:1 ratio of test article to placebo.
Subjects will be asked to use the study products on a daily basis for the duration of the 24-week study. Subjects will take one capsule twice daily (one in the morning and one in the evening) and will be asked to use 3-7mL of the shampoo, 3-7mL of the conditioner, and 1mL of the topical nutriment daily. Subjects will receive detailed instructions regarding the order and duration of application of each product.
Subjects in the active arm will receive active capsules, shampoo, conditioner and topical nutriment. Subjects on placebo will receive placebo capsules, shampoo, conditioner and topical nutriment. All subjects will be instructed to take the capsules orally, one in the morning and one in the evening, prior to consuming food. Shampoo and conditioner are to be used once per day when washing the hair and nutriment applied at the end of the day prior to bedtime. To facilitate this, subjects will receive a 3-month supply of each product (supplement, shampoo, conditioner, and scalp nutriment). Subjects will continue the daily regimen for 24 weeks, visiting the clinic at week 12 for an interim assessment.
Conditions
- Androgenetic Alopecia
- Androgenic Alopecia
- Telogen Effluvium
- Thinning Hair
- Hair Loss/Baldness
- Hair Thinning
Interventions
- DIETARY_SUPPLEMENT
-
ALRV5XR
ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal. There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)
- OTHER
-
ALRV5XR Shampoo
ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
- OTHER
-
ALRV5XR Conditioner
ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
- OTHER
-
ALRV5XR Hair Follicle Serum (Nutriment)
ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night. Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)
- DIETARY_SUPPLEMENT
-
Placebo
Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal. There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)
- OTHER
-
Placebo Shampoo
Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
- OTHER
-
Placebo Conditioner
Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
- OTHER
-
Placebo Hair Follicle Serum (Nutriment)
Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night. Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)
Sponsors & Collaborators
-
Arbor Life Labs
lead INDUSTRY
Principal Investigators
-
Luciano Marra (Medical Director), PhD · Arbor Life Labs
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-11
- Primary Completion
- 2018-10-23
- Completion
- 2018-10-23
Countries
- United States
Study Locations
More Related Trials
-
Microarray Analysis of Scalp Biopsies After Minoxidil Treatment
NCT01309191 ·Status: COMPLETED ·Phase: NA
-
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
NCT02460289 ·Status: COMPLETED ·Phase: NA
-
An Exploratory Clinical Study to Assess Safety, Efficacy and In-Use Tolerability of Three Different Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III)
NCT06556056 ·Status: COMPLETED ·Phase: NA
-
Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia
NCT05864885 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes
NCT07203599 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
NCT05802173 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness and Safety of Platelet-rich Plasma and Topical 5% Minoxidil Combination in Male Androgenetic Alopecia
NCT06043349 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
NCT02503137 ·Status: COMPLETED ·Phase: PHASE2
-
Minoxidil Response Testing in Males With Androgenetic Alopecia
NCT02198261 ·Status: COMPLETED
-
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
NCT02279823 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
NCT06826196 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia
NCT02074943 ·Status: UNKNOWN ·Phase: NA
-
Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
NCT03852992 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
NCT05914805 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
NCT06501924 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia
NCT02848300 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia
NCT01501617 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Role of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata
NCT05587257 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
NCT00151515 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
NCT04518995 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
NCT05636904 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men
NCT05989165 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of PRP on the Therapy for Hair Growth
NCT02087319 ·Status: COMPLETED ·Phase: NA
-
PF-06651600 for the Treatment of Alopecia Areata
NCT03732807 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia
NCT05827991 ·Status: UNKNOWN ·Phase: NA